Once-a-week Alendronate (Fosamax)
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for once-a-week use is under development and may be available next year....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Once-a-week Alendronate (Fosamax)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1100
Article Code: 1100c
Date: March 19, 2001
Volume: 43
Page: 26
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1100
Article Code: 1100c
Date: March 19, 2001
Volume: 43
Page: 26
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)